Evidence map›Paper›PMID 28215481›Full record

ArticleJournal of epidemiology2017

Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project.

Shigekazu Ukawa, Koshi Nakamura, Emiko Okada, Makoto Hirata, Akiko Nagai, Zentaro Yamagata, Kaori Muto, Koichi Matsuda, Toshiharu Ninomiya, Yutaka Kiyohara and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shigekazu UkawaDepartment of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Koshi NakamuraDepartment of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Emiko OkadaDepartment of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Makoto HirataLaboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akiko NagaiDepartment of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Zentaro YamagataDepartment of Health Sciences, University of Yamanashi, Yamanashi, Japan.
Kaori MutoDepartment of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koichi MatsudaLaboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toshiharu NinomiyaDepartment of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yutaka KiyoharaHisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan.
Yoichiro KamataniLaboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Yusuke NakamuraLaboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
BioBank Japan Cooperative Hospital Group
Akiko TamakoshiDepartment of Public Health, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. Electronic address: tamaa@med.hokudai.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is the sixth leading cause of cancer-related deaths in Japan. We aimed to elucidate the clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan (BBJ) project.

methodsFour thousand, seven hundred and ninety-three patients diagnosed with prostate cancer in the BBJ project were included. Clinical and histopathological data, including causes of death, were analyzed. Relative survival (RS) rates of prostate cancer were calculated.

resultsFour thousand, one hundred and seventy-one prostate cancer patients with available histological data had adenocarcinoma. The mean age of the patients was 72.5 years. The proportion of patients who were non-smokers, non-drinkers, had a normal body mass index, did not exercise, had a normal prostate-specific antigen level, and had a family history of prostate cancer were 30.7%, 28.0%, 66.6%, 58.1%, 67.6%, and 6.5%, respectively. The proportion of patients with Stage II, III, and IV disease were 24.4%, 7.3%, and 4.4%, respectively. After limiting to patients with a time from the initial diagnosis of prostate cancer to entry into the study cohort of ≤90 days (n = 869), the 5- and 10-year RS rates were 96.3% and 100.5%, respectively, although we were unable to consider management strategies due to a plenty of data missing.

conclusionsWe provide an overview of patients with prostate cancer in the BBJ project. Our findings, coupled with those from various high throughput "omics" technologies, will contribute to the implementation of prevention interventions and medical management of prostate cancer patients.

Indexed as

Biological Specimen BanksAdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCause of DeathFollow-Up StudiesHumansJapanLife StyleMaleMiddle AgedNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorProstate-Specific AntigenBioBank Japan projectLifestyleProstate cancerSurvivalTumor biomarker

Identifiers

PMID28215481
PMCPMC5350593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.